Shorla Oncology & EVERSANA Announce Commercial Launch of Recent FDA-Approved Nelarabine Injection for the Treatment of T-cell Leukemia Across the United States
Shorla Oncology, a U.S.-Ireland pharmaceutical company, and EVERSANA®, a leading provider of commercialization services to the life science industry, today announced the commercial launch of the company’s oncology drug, Nelarabine Injection, for the treatment of T-cell Acute Lymphoblastic Leukemia (T-ALL) and T-cell Lymphoblastic Lymphoma (T-LBL) in adult and pediatric patients aged one year and older whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens. Read more here.
EVERSANA® Announces Partnership with ChemoMouthpiece, LLC to Support U.S. Launch & Commercialization of Medical Device to Help Cancer Patients Manage and Treat Oral Mucositis
EVERSANA®, a leading provider of commercialization services to the life science industry, today announced a partnership with ChemoMouthpiece, LLC to support the launch and commercialization of its medical device, the Chemo Mouthpiece™, to assist oncology patients across the United States. Read more here.
Xspray Pharma Partners with EVERSANA® for the U.S. Launch and Commercialization of its Lead Product, Dasynoc (XS004) for the Treatment of Chronic Myeloid Leukemia (CML) and Acute Lymphatic Leukemia (ALL)
Xspray Pharma AB, (NASDAQ Stockholm: XSPRAY) has signed an agreement with EVERSANA® to support the U.S. launch and commercialization of the company’s first innovative cancer therapy Dasynoc for the treatment of chronic myeloid leukemia (CML) and acute lymphatic leukemia (ALL). While maintaining financial and strategic control, Xspray Pharma will grant EVERSANA exclusive commercialization access to support its Dasynoc launch, aimed at the second half of 2023. Dasynoc, pending FDA-approval and legal conditions, will be a new and differentiated treatment option for CML and ALL patients, entering the $3.5 billion commercial market for Tyrosine Kinase Inhibitors in the United States – a market that has grown by nearly 5% in the last year alone. Read more here.
U.K.-based Nemaura Taps EVERSANA to Support Large-Scale Launch of Nemaura’s Diabetes Management Program in the U.S.
Nemaura Medical, Inc.(NASDAQ: NMRD) a medical technology company focused on developing and commercialising noninvasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, has announced that it has entered into a preliminary agreement with EVERSANA® to support all global sales and marketing of Nemaura’s Diabetes Management Solution, BEATdiabetes. Nemaura and EVERSANA will work together to develop the optimal launch strategy for large-scale adoption of the diabetes management program, including franchising and direct sales to self-insured corporate clients and healthcare insurers. Read more here.
Prosoma Digital Therapeutics and EVERSANA Announce Commercialisation Partnership for New Therapeutic Supporting Mental Health and Behavioural Needs of Cancer Patients
Prosoma Digital Therapeutics, innovators in reinventing healthcare for oncology patients, has partnered with EVERSANA® to support the expected launch and commercialisation for Prosoma’s digital therapy to support the mental health of cancer patients. Read more here.
OWP Pharmaceuticals and EVERSANA Announce Partnership to Commercialize Oral Liquid Formulations to Treat Neuroscience Disorders
Australian AI Company Artrya Announces Major UK Commercialisation Partnership With EVERSANA
AI medical technology company Artrya Limited announced its partnership with leading global commercial services provider EVERSANA as its launch and commercialisation partner to access the UK market. Read the full story.
Q BioMed Bolsters Commercialization of Strontium89 with EVERSANA Partnership
Q BioMed Inc. a biotech acceleration and commercial stage company focused on licensing and acquiring undervalued biomedical assets in the healthcare sector, today announced it has engaged EVERSANA™ to immediately support the commercialization of Strontium89, an FDA-approved cancer bone palliation radiotherapy. Read the full story.
MINDPAX and EVERSANA announce U.S. commercialization partnership to launch revolutionary digital therapeutic solution for bipolar disorders
The leadership team at MINDPAX Inc., the leading digital therapeutic company focused on bipolar disorders, today announces its partnership with EVERSANA™ to launch and commercialize its therapeutics in the United States. MINDPAX combines remote clinical assessment and targeted digital therapy to improve patients’ clinical conditions. Read the full story.
Shorla Pharma Announces Partnership with EVERSANA to Support the Launch and Commercialization of T-cell Leukemia Treatment
Shorla Pharma (‘Shorla’), a specialty pharmaceutical company, and EVERSANA™, the pioneer of next generation commercial services to the global life sciences industry, today announced a partnership to support the launch and commercialization of Shorla’s oncology portfolio. Read the full story.
GENinCode announces major US commercialisation partnership with EVERSANA
GENinCode UK Limited, the cardiovascular disease company focused on predictive genetics for the prevention of cardiovascular disease, is partnering with EVERSANA to be the launch and commercialisation partner to access the United States market for the GENinCode portfolio of polygenic cardiovascular disease (“CVD”) products focused on genetic risk. Read the full story.
Resverlogix and EVERSANA Announce Partnership to Support the Launch of Apabetalone for COVID-19 in the United States and Canada
Resverlogix Corp. and EVERSANA announced a partnership to support planned commercialization of apabetalone in the United States, Canada (where authorization has been granted to conduct clinical studies of apabetalone for COVID-19) and/or potentially expanding to additional global markets, as Emergency Use Authorization and/or a New Drug Application or equivalent is issued or approved. Read the full story.
